PeptideScanner retained ClinicalTrials.gov record NCT07657676 at 2026-07-30T16:19:03.062Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was mazdutide.
PeptideScanner retained ClinicalTrials.gov record NCT07650240 at 2026-07-30T16:19:03.043Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT07654062 at 2026-07-30T16:19:03.055Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was mazdutide.
PeptideScanner retained ClinicalTrials.gov record NCT05726227 at 2026-07-30T16:19:03.202Z. Its registry update date was 2026-06-16, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07027124 at 2026-07-30T16:19:03.054Z. Its registry update date was 2026-06-16, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT06326190 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-15, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT07413913 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-15, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT05605964 at 2026-07-30T16:19:03.061Z. Its registry update date was 2026-06-15, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT04592744 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00329043 at 2026-07-30T16:19:03.050Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT07226765 at 2026-07-30T16:19:03.046Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07225686 at 2026-07-30T16:19:03.064Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07382024 at 2026-07-30T16:19:03.058Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06864026 at 2026-07-30T16:19:03.062Z. Its registry update date was 2026-06-11, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06305598 at 2026-07-30T16:19:03.055Z. Its registry update date was 2026-06-10, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT07282769 at 2026-07-30T16:19:03.054Z. Its registry update date was 2026-06-10, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07462663 at 2026-07-30T16:19:03.043Z. Its registry update date was 2026-06-10, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04467983 at 2026-07-30T16:19:03.055Z. Its registry update date was 2026-06-08, and PeptideScanner's reviewed identity mapping was abaloparatide.
PeptideScanner retained ClinicalTrials.gov record NCT04529044 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT06976853 at 2026-07-30T16:19:03.055Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07218445 at 2026-07-30T16:19:03.065Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07630454 at 2026-07-30T16:19:03.064Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT04167163 at 2026-07-30T16:19:03.051Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was abaloparatide.
PeptideScanner retained ClinicalTrials.gov record NCT04954820 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT07401862 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT05424003 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07228741 at 2026-07-30T16:19:03.065Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07627074 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07204249 at 2026-07-30T16:19:03.057Z. Its registry update date was 2026-06-03, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07614438 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-06-02, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT06571383 at 2026-07-30T16:19:03.050Z. Its registry update date was 2026-06-02, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06161584 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-06-01, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT06482112 at 2026-11-16T17:46:45.897Z. Its registry update date was 2026-06-01, and PeptideScanner's reviewed identity mapping was efinopegdutide.
PeptideScanner retained ClinicalTrials.gov record NCT03290950 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-05-29, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT07610174 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-29, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05774756 at 2026-07-30T16:19:36.905Z. Its registry update date was 2026-05-29, and PeptideScanner's reviewed identity mapping was setmelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT06485089 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-28, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07469800 at 2026-07-30T16:19:36.903Z. Its registry update date was 2026-05-27, and PeptideScanner's reviewed identity mapping was mazdutide.
PeptideScanner retained ClinicalTrials.gov record NCT04126070 at 2026-07-30T16:19:36.912Z. Its registry update date was 2026-05-27, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT05333003 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-27, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06704763 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-05-26, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06186622 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06337838 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT07605247 at 2026-07-30T16:19:36.902Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT02860923 at 2026-07-30T16:19:36.924Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT06373731 at 2026-07-30T16:19:36.914Z. Its registry update date was 2026-05-20, and PeptideScanner's reviewed identity mapping was elamipretide.
PeptideScanner retained ClinicalTrials.gov record NCT04469855 at 2026-07-30T16:19:36.922Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01293292 at 2026-07-30T16:19:36.921Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT06554717 at 2026-07-30T16:19:36.918Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was tesamorelin.
PeptideScanner retained ClinicalTrials.gov record NCT05989711 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-18, and PeptideScanner's reviewed identity mapping was pemvidutide.
PeptideScanner retained ClinicalTrials.gov record NCT06041217 at 2026-07-30T16:19:36.910Z. Its registry update date was 2026-05-18, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00544830 at 2026-07-30T16:19:36.909Z. Its registry update date was 2026-05-15, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT07557953 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-15, and PeptideScanner's reviewed identity mapping was cagrilintide.
PeptideScanner retained ClinicalTrials.gov record NCT05652205 at 2026-07-30T16:19:36.913Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was linaclotide.
PeptideScanner retained ClinicalTrials.gov record NCT05151484 at 2026-07-30T16:19:36.911Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT07523633 at 2026-07-30T16:19:36.919Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03770338 at 2026-07-30T16:19:36.903Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT07379333 at 2026-11-16T17:34:46.889Z. Its registry update date was 2026-05-13, and PeptideScanner's reviewed identity mapping was efpeglenatide.
PeptideScanner retained ClinicalTrials.gov record NCT03934684 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT04427241 at 2026-11-16T17:33:14.861Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT01155232 at 2026-07-30T16:19:36.922Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT05586802 at 2026-07-30T16:19:36.909Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07059377 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05959252 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-05-08, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT06734273 at 2026-07-30T16:19:36.910Z. Its registry update date was 2026-05-08, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT05137119 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT04575844 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07298915 at 2026-07-30T16:19:36.919Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT04019197 at 2026-07-30T16:19:36.918Z. Its registry update date was 2026-05-04, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07443956 at 2026-07-30T16:19:36.909Z. Its registry update date was 2026-05-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07554638 at 2026-07-30T16:19:36.907Z. Its registry update date was 2026-05-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT04194554 at 2026-07-30T16:19:36.919Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02944500 at 2026-07-30T16:19:36.903Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03856632 at 2026-07-30T16:19:36.910Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06176365 at 2026-07-30T16:20:49.317Z. Its registry update date was 2026-04-30, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT06309992 at 2026-07-30T16:20:49.307Z. Its registry update date was 2026-04-30, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT07495722 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT07304466 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT04174755 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05500586 at 2026-07-30T16:20:49.307Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT03841058 at 2026-07-30T16:20:49.320Z. Its registry update date was 2026-04-28, and PeptideScanner's reviewed identity mapping was abaloparatide.
PeptideScanner retained ClinicalTrials.gov record NCT07065552 at 2026-07-30T16:20:49.313Z. Its registry update date was 2026-04-28, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT05982093 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-04-24, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT04961528 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-04-23, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT05646706 at 2026-07-30T16:20:49.307Z. Its registry update date was 2026-04-23, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06283667 at 2026-07-30T16:20:49.310Z. Its registry update date was 2026-04-22, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01816971 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT04572854 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT04428008 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
PeptideScanner retained ClinicalTrials.gov record NCT06124807 at 2026-07-30T16:20:49.321Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was mazdutide.
PeptideScanner retained ClinicalTrials.gov record NCT05746039 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06424106 at 2026-07-30T16:20:49.305Z. Its registry update date was 2026-04-20, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT06657209 at 2026-07-30T16:20:49.310Z. Its registry update date was 2026-04-20, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT05482789 at 2026-07-30T16:20:49.324Z. Its registry update date was 2026-04-20, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT06558188 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-17, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT05951400 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-04-15, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT06811324 at 2026-07-30T16:20:49.320Z. Its registry update date was 2026-04-15, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06256432 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT07411560 at 2026-07-30T16:20:49.304Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was cagrilintide.
PeptideScanner retained ClinicalTrials.gov record NCT02772588 at 2026-07-30T16:20:49.312Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02960022 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT06751589 at 2026-07-30T16:20:49.318Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT05738148 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-04-09, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT05048901 at 2026-07-30T16:20:49.324Z. Its registry update date was 2026-04-09, and PeptideScanner's reviewed identity mapping was lanreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02127437 at 2026-07-30T16:20:49.305Z. Its registry update date was 2026-04-08, and PeptideScanner's reviewed identity mapping was lanreotide.
PeptideScanner retained ClinicalTrials.gov record NCT07338214 at 2026-07-30T16:20:49.304Z. Its registry update date was 2026-04-08, and PeptideScanner's reviewed identity mapping was petrelintide.
PeptideScanner retained ClinicalTrials.gov record NCT00302822 at 2026-11-16T01:41:15.051Z. Its registry update date was 2026-04-07, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT07104383 at 2026-11-16T17:46:36.579Z. Its registry update date was 2026-04-07, and PeptideScanner's reviewed identity mapping was vk2735.
PeptideScanner retained ClinicalTrials.gov record NCT04983901 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-04-06, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT06275555 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-04-06, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT06604624 at 2026-07-30T16:20:49.309Z. Its registry update date was 2026-04-06, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01813227 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-04-03, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT02892942 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-04-03, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT03119584 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-03, and PeptideScanner's reviewed identity mapping was linaclotide.
PeptideScanner retained ClinicalTrials.gov record NCT00120367 at 2026-11-16T01:41:15.051Z. Its registry update date was 2026-04-02, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT05809531 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-04-02, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT06264609 at 2026-07-30T16:20:49.326Z. Its registry update date was 2026-04-01, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT06734130 at 2026-07-30T16:20:49.318Z. Its registry update date was 2026-04-01, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT04040088 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT04069299 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT07126262 at 2026-07-30T16:22:22.346Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was vosoritide.
PeptideScanner retained ClinicalTrials.gov record NCT06807437 at 2026-07-30T16:22:22.334Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was lanreotide.
PeptideScanner retained ClinicalTrials.gov record NCT03139305 at 2026-07-30T16:22:22.326Z. Its registry update date was 2026-03-30, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT02817659 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-30, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT07499882 at 2026-07-30T16:22:22.324Z. Its registry update date was 2026-03-30, and PeptideScanner's reviewed identity mapping was ziconotide.
PeptideScanner retained ClinicalTrials.gov record NCT04261855 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT05954962 at 2026-11-15T22:03:26.540Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT06471361 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was zilucoplan.
PeptideScanner retained ClinicalTrials.gov record NCT05933499 at 2026-07-30T16:22:22.327Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06118203 at 2026-07-30T16:22:22.346Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07220473 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-24, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT04919629 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT06662539 at 2026-07-30T16:22:22.334Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was petrelintide.
PeptideScanner retained ClinicalTrials.gov record NCT02773030 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT06378268 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT07009860 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was pemvidutide.
PeptideScanner retained ClinicalTrials.gov record NCT07227948 at 2026-07-30T16:22:22.326Z. Its registry update date was 2026-03-19, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05659147 at 2026-11-16T01:34:15.953Z. Its registry update date was 2026-03-18, and PeptideScanner's reviewed identity mapping was secretin.
PeptideScanner retained ClinicalTrials.gov record NCT04219007 at 2026-07-30T16:22:22.347Z. Its registry update date was 2026-03-18, and PeptideScanner's reviewed identity mapping was vosoritide.
PeptideScanner retained ClinicalTrials.gov record NCT06934655 at 2026-07-30T16:22:22.326Z. Its registry update date was 2026-03-17, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06989177 at 2026-07-30T16:22:22.331Z. Its registry update date was 2026-03-17, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06989203 at 2026-07-30T16:22:22.329Z. Its registry update date was 2026-03-17, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04488081 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-03-16, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT03989947 at 2026-07-30T16:22:22.327Z. Its registry update date was 2026-03-13, and PeptideScanner's reviewed identity mapping was vosoritide.
PeptideScanner retained ClinicalTrials.gov record NCT02724228 at 2026-07-30T16:22:22.336Z. Its registry update date was 2026-03-13, and PeptideScanner's reviewed identity mapping was vosoritide.
PeptideScanner retained ClinicalTrials.gov record NCT04554940 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-13, and PeptideScanner's reviewed identity mapping was vosoritide.
PeptideScanner retained ClinicalTrials.gov record NCT02572323 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-12, and PeptideScanner's reviewed identity mapping was tesamorelin.
PeptideScanner retained ClinicalTrials.gov record NCT07468552 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06252493 at 2026-07-30T16:22:22.324Z. Its registry update date was 2026-03-12, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT04228289 at 2026-11-16T00:59:19.138Z. Its registry update date was 2026-03-11, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT07213466 at 2026-07-30T16:22:22.332Z. Its registry update date was 2026-03-11, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01572480 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-03-10, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT05845749 at 2026-07-30T16:22:22.324Z. Its registry update date was 2026-03-10, and PeptideScanner's reviewed identity mapping was vosoritide.
PeptideScanner retained ClinicalTrials.gov record NCT07460908 at 2026-07-30T16:22:22.346Z. Its registry update date was 2026-03-10, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT06330805 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-09, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00936390 at 2026-07-30T16:22:22.345Z. Its registry update date was 2026-03-06, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT05965908 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-06, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06295952 at 2026-11-15T22:05:38.400Z. Its registry update date was 2026-03-04, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT05681299 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-04, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06461910 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-03-03, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
PeptideScanner retained ClinicalTrials.gov record NCT02653092 at 2026-11-16T17:31:07.936Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was gonadorelin.
PeptideScanner retained ClinicalTrials.gov record NCT07345494 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was palopegteriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT03946527 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was lanreotide.
PeptideScanner retained ClinicalTrials.gov record NCT05700903 at 2026-07-30T16:22:22.343Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT03633708 at 2026-11-15T22:07:29.454Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT06027567 at 2026-07-30T16:23:45.644Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06759701 at 2026-07-30T16:23:45.658Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07095517 at 2026-07-30T16:23:45.642Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT05896566 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-02-24, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT05891496 at 2026-07-30T16:23:45.669Z. Its registry update date was 2026-02-24, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01786265 at 2026-07-30T16:23:45.644Z. Its registry update date was 2026-02-20, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT07423247 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-20, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT04711135 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT06760546 at 2026-07-30T16:23:45.658Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was setmelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT05320406 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT06517212 at 2026-07-30T16:23:45.659Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT03899961 at 2026-11-16T00:59:19.138Z. Its registry update date was 2026-02-10, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT06939088 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-10, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT03275285 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-02-09, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT00903110 at 2026-11-16T17:35:13.282Z. Its registry update date was 2026-02-06, and PeptideScanner's reviewed identity mapping was mecasermin.
PeptideScanner retained ClinicalTrials.gov record NCT00066703 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-02-06, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT03879694 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-06, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT03902951 at 2026-07-30T16:23:45.660Z. Its registry update date was 2026-02-05, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT04455750 at 2026-07-30T16:23:45.647Z. Its registry update date was 2026-02-05, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT07366710 at 2026-07-30T16:23:45.659Z. Its registry update date was 2026-02-02, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT06916065 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-01-30, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT06914102 at 2026-07-30T16:25:18.004Z. Its registry update date was 2026-01-30, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06914154 at 2026-07-30T16:25:18.014Z. Its registry update date was 2026-01-30, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT05067127 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-01-29, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT04251156 at 2026-07-30T16:25:18.009Z. Its registry update date was 2026-01-29, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07364175 at 2026-07-30T16:25:18.007Z. Its registry update date was 2026-01-29, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07076030 at 2026-07-30T16:25:18.009Z. Its registry update date was 2026-01-28, and PeptideScanner's reviewed identity mapping was petrelintide.
PeptideScanner retained ClinicalTrials.gov record NCT04734730 at 2026-07-30T16:25:18.017Z. Its registry update date was 2026-01-28, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT07373834 at 2026-07-30T16:25:18.006Z. Its registry update date was 2026-01-28, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06445075 at 2026-07-30T16:25:18.017Z. Its registry update date was 2026-01-23, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07229157 at 2026-07-30T16:25:18.016Z. Its registry update date was 2026-01-23, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03972488 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-01-21, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT05788965 at 2026-07-30T16:25:18.013Z. Its registry update date was 2026-01-21, and PeptideScanner's reviewed identity mapping was semaglutide.